Literature DB >> 2573436

Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia.

W W Choi1, M P Mehta, D J Murray, M D Sokoll, R B Forbes, S D Gergis, M Abou-Donia, J Kirchner.   

Abstract

The neuromuscular and cardiovascular effects of mivacurium chloride were studied during nitrous oxide-oxygen narcotic (fentanyl) (n = 90) and nitrous oxide-oxygen isoflurane (ISO) anaesthesia (n = 45). In addition, a separate group (n = 9) received succinylcholine during fentanyl anaesthesia to compare its neuromuscular effects with mivacurium. Mivacurium was initially administered as a single bolus in doses from 0.03 mg.kg-1 to 0.25 mg.kg-1 to study the dose-response relationships, as well as the cardiovascular effects of mivacurium. Neuromuscular block (NMB) was measured by recording the twitch response of the adductor pollicis muscle following ulnar nerve stimulation (0.15 Hz, 0.2 ms supramaximal voltage). The ED95 values for mivacurium were estimated to be 0.073 mg.kg-1 and 0.053 mg.kg-1 in the fentanyl and ISO groups respectively. The duration of block (time from injection to 95 per cent recovery) for a dose of 0.05 mg.kg-1 mivacurium was 15.3 +/- 1.0 min and 21.5 +/- 1.3 min for fentanyl and ISO anaesthesia, respectively. The recovery index (25-75 per cent) between initial bolus dose (6.1 +/- 0.5 min), repeat bolus doses (7.6 +/- 0.6 min), mivacurium infusion (6.7 +/- 0.7 min) and succinylcholine infusion (6.8 +/- 1.8 min) were not significantly different. There was minimal change in mean arterial pressure (MAP) or heart rate (HR) following bolus doses of mivacurium up to 0.15 mg.kg-1. Bolus administration of 0.20 mg.kg-1 or 0.25 mg.kg-1 of mivacurium decreased MAP from 78.2 +/- 2.5 to 64.0 +/- 3.2 mmHg (range 12-59 per cent of control) (P less than 0.05). The same doses when administered slowly over 30 sec produced minimal change in MAP or HR.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573436     DOI: 10.1007/BF03005415

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  17 in total

1.  Does clinical anesthesia need new neuromuscular blocking agents?

Authors:  J J Savarese; R J Kitz
Journal:  Anesthesiology       Date:  1975-03       Impact factor: 7.892

2.  Pathophysiology of hyperkalemia induced by succinylcholine.

Authors:  G A Gronert; R A Theye
Journal:  Anesthesiology       Date:  1975-07       Impact factor: 7.892

3.  The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.

Authors:  J J Savarese; H H Ali; S J Basta; P B Embree; R P Scott; N Sunder; J N Weakly; W B Wastila; H A el-Sayad
Journal:  Anesthesiology       Date:  1988-05       Impact factor: 7.892

4.  Mivacurium chloride (BW B1090U)-induced neuromuscular blockade during nitrous oxide-isoflurane and nitrous oxide-narcotic anesthesia in adult surgical patients.

Authors:  S Weber; B W Brandom; D M Powers; J B Sarner; S K Woelfel; D R Cook; V J Foster; B F McNulty; J N Weakly
Journal:  Anesth Analg       Date:  1988-06       Impact factor: 5.108

5.  The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia.

Authors:  J J Savarese; H H Ali; S J Basta; R P Scott; P B Embree; W B Wastila; M M Abou-Donia; C Gelb
Journal:  Anesthesiology       Date:  1989-03       Impact factor: 7.892

6.  Safety and efficacy of atracurium (BW33A) in surgical patients receiving balanced or isoflurane anesthesia.

Authors:  M D Sokoll; S D Gergis; M Mehta; N M Ali; C Lineberry
Journal:  Anesthesiology       Date:  1983-05       Impact factor: 7.892

7.  Neuromuscular and cardiovascular effects of mivacurium in children.

Authors:  N G Goudsouzian; J K Alifimoff; C Eberly; R Smeets; J Griswold; V Miler; B F McNulty; J J Savarese
Journal:  Anesthesiology       Date:  1989-02       Impact factor: 7.892

8.  The dose-response relationship of mivacurium chloride in humans during nitrous oxide-fentanyl or nitrous oxide-enflurane anesthesia.

Authors:  J E Caldwell; J B Kitts; T Heier; M R Fahey; D P Lynam; R D Miller
Journal:  Anesthesiology       Date:  1989-01       Impact factor: 7.892

9.  Clinical pharmacology of mivacurium chloride (BW B1090U) in children during nitrous oxide-halothane and nitrous oxide-narcotic anesthesia.

Authors:  J B Sarner; B W Brandom; S K Woelfel; M L Dong; M C Horn; D R Cook; B F McNulty; V J Foster
Journal:  Anesth Analg       Date:  1989-02       Impact factor: 5.108

10.  Clinical characteristics of long-term succinylcholine neuromuscular blockade during balanced anesthesia.

Authors:  F M Ramsey; P W Lebowitz; J J Savarese; H H Ali
Journal:  Anesth Analg       Date:  1980-02       Impact factor: 5.108

View more
  6 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Apology.

Authors:  W W Choi; R P From; K S Pearson; M D Sokoll
Journal:  Can J Anaesth       Date:  1991-04       Impact factor: 5.063

3.  Early neuromuscular recovery characteristics following administration of mivacurium plus vecuronium.

Authors:  R G Stout; S J Brull; D Kelly; D G Silverman
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

Review 4.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 5.  Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.

Authors:  James E Frampton; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  New developments in nondepolarizing muscle relaxants.

Authors:  R K Mirakhur
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.